Cystatin C, a Controversial Biomarker in Hypothyroid Patients under Levothyroxine Therapy: THYRenal, a Pilot Cohort Observational Study.

Marta Greco Daniela Patrizia Foti Antonio AversaGiorgio FuianoAntonio BrunettiMariadelina Simeoni

Published in: Journal of clinical medicine (2020)

The observation of increased serum Cys-C in patients with suboptimal TSH would suggest the importance of a careful interpretation by clinicians of this biomarker in the case of hypothyroid patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
peritoneal dialysis
clinical trial
mesenchymal stem cells
study protocol
cell therapy